文献速递白血病造血干细胞移植与细胞治疗

在人急性髓系白血病小鼠异种移植模型中优化嵌合抗原受体T细胞清除策略

Optimized depletion of chimeric antigen receptor T cells in murine xenograft models of human acute myeloid leukemia.
PubMed 文献 · Blood · 2017-02-28

研究在临床前人类急性髓系白血病(AML)小鼠异种移植模型中比较三种CAR T细胞终止策略:瞬时活性RNA-CART123、阿仑单抗清除CART123、利妥昔单抗清除CART123-CD20。所有策略均快速消除白血病,抗体介导清除未损害缓解,持久缓解需CAR T细胞维持4周后再清除,终止后成功实现正常供者造血植入。

要点

  • 三种CAR T细胞终止策略均在小鼠异种移植模型中快速消除人类AML。
  • 抗体介导清除CART123或CART123-CD20未损害白血病缓解。
  • 持久白血病缓解要求CAR T细胞在清除前维持4周。

核心结论

  • 优化时机清除CAR T细胞可在AML消除后保留白血病缓解,并允许后续造血干细胞移植。

研究设计与样本

  • 研究在人类AML小鼠异种移植模型中比较三种CAR T细胞终止策略:瞬时活性抗CD123 mRNA电穿孔CART(RNA-CART123)、慢病毒转导抗CD123-4-1BB-CD3ζ T细胞(CART123)后使用阿仑单抗清除T细胞、共表达CD20的CART123(CART123-CD20)后使用利妥昔单抗清除T细胞。

主要发现

  • 所有三种策略均导致小鼠异种移植模型中人类AML快速消除。
  • 后续抗体介导清除CART123或CART123-CD20未损害白血病缓解。
  • 时间进程研究表明,持久白血病缓解要求CAR T细胞在清除前维持4周。
  • CAR T细胞终止后,使用正常人类供者成功实现造血植入,以模拟异基因干细胞救援。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

We and others previously reported potent antileukemia efficacy of CD123-redirected chimeric antigen receptor (CAR) T cells in preclinical human acute myeloid leukemia (AML) models at the cost of severe hematologic toxicity. This observation raises concern for potential myeloablation in patients with AML treated with CD123-redirected CAR T cells and mandates novel approaches for toxicity mitigation. We hypothesized that CAR T-cell depletion with optimal timing after AML eradication would preserve leukemia remission and allow subsequent hematopoietic stem cell transplantation. To test this hypothesis, we compared 3 CAR T-cell termination strategies: (1) transiently active anti-CD123 messenger RNA-electroporated CART (RNA-CART123); (2) T-cell ablation with alemtuzumab after treatment with lentivirally transduced anti-CD123-4-1BB-CD3ζ T cells (CART123); and (3) T-cell ablation with rituximab after treatment with CD20-coexpressing CART123 (CART123-CD20). All approaches led to rapid leukemia elimination in murine xenograft models of human AML. Subsequent antibody-mediated depletion of CART123 or CART123-CD20 did not impair leukemia remission. Time-course studies demonstrated that durable leukemia remission required CAR T-cell persistence for 4 weeks prior to ablation. Upon CAR T-cell termination, we further demonstrated successful hematopoietic engraftment with a normal human donor to model allogeneic stem cell rescue. Results from these studies will facilitate development of T-cell depletion strategies to augment the feasibility of CAR T-cell therapy for patients with AML.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Tasian SK, Kenderian SS, Shen F, et al. Optimized depletion of chimeric antigen receptor T cells in murine xenograft models of human acute myeloid leukemia. Blood. 2017. PMID: 28246194. doi:10.1182/blood-2016-08-736041

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。